Response to Letter to the Editor: Fully COVID ‐19 Vaccinated Status Enhanced the Efficacy of Immune Checkpoint Inhibitors in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Key Points

• Efficacy of immune checkpoint inhibitors increases with fully vaccinated status against COVID-19.
• Patients with recurrent or metastatic head and neck squamous cell carcinoma benefit from enhanced treatment response with said vaccination.
• Commentary discusses observations rather than presenting original findings or data insights.
• Supports the idea that COVID-19 vaccination may play a role in cancer treatment outcomes.

Abstract